¦hµo©Êµw¤Æ¯g±wªÌ¿íÂåÅñ©Ê°ª¡@§U´î¤Öªñ¤T¦¨µo¯f²v

2016-05-13 1296

®Ú¾Ú²Î­p¡A¥Ø«e¥þ¥xªñ2000¤H¿©±w¦hµo©Êµw¤Æ¯g¡A¦nµo±Ú¸s¥D­n¬O20~40·³ªº¦¨¤H¡Aµo¯f­ì¦]¥D­n¬O¦]¬°¤¤¼Ï¯«¸g¨t²Î²£¥Í¤£¥¿±`ªº§K¬Ì¤ÏÀ³¾É­Pµoª¢¡A¶i¦Ó³y¦¨¤¤¼Ï¯«¸g¯fÅÜ¡C¥Ñ©ó¤HÃþªº¯«¸g¨t²Î¨ü·l«á¤£©ö­×´_¡A¦]¦¹¦³®Ä±±¨î¯fµ{ªº¶i®i»P´_µo¡A¬O¦hµo©Êµw¤Æ¯gªvÀøªº­«ÂI¡CµM¦Ó³\¦h¯f±w«o¦]­Ó¤H¹ï¯e¯f­·ÀIªº»{ª¾¤£¨¬¡B¾á¤ß

®Ú¾Ú²Î­p¡A¥Ø«e¥þ¥xªñ2000¤H¿©±w¦hµo©Êµw¤Æ¯g¡A¦nµo±Ú¸s¥D­n¬O20~40·³ªº¦¨¤H¡Aµo¯f­ì¦]¥D­n¬O¦]¬°¤¤¼Ï¯«¸g¨t²Î²£¥Í¤£¥¿±`ªº§K¬Ì¤ÏÀ³¾É­Pµoª¢¡A¶i¦Ó³y¦¨¤¤¼Ï¯«¸g¯fÅÜ¡C¥Ñ©ó¤HÃþªº¯«¸g¨t²Î¨ü·l«á¤£©ö­×´_¡A¦]¦¹¦³®Ä±±¨î¯fµ{ªº¶i®i»P´_µo¡A¬O¦hµo©Êµw¤Æ¯gªvÀøªº­«ÂI¡CµM¦Ó³\¦h¯f±w«o¦]­Ó¤H¹ï¯e¯f­·ÀIªº»{ª¾¤£¨¬¡B¾á¤ß»P¨ä¥L¯e¯f¦X¨ÖªvÀø·|¦³¥æ¤e¤ÏÀ³¡B¤ß²z®£Äß¡B®`©È¥ÎÃİƧ@¥Î¡Kµ¥¦]¯À¡A¼vÅT¥ÎÃĪº¿íÂåÅñ©Ê¡A¤Ï¦Ó¹ï¯e¯f¶iµ{®e©ö³y¦¨¤£¨}ªº¼vÅT¡C

¥ÎÃĶ¶±q©Ê°ª¡@¦³§U±±¨î¯f±¡

°ª¶¯Âå¾Ç¤j¾Ç¯«¸g¤º¬ì¥DªvÂå®v¿c¬Û¦pÂå®vªí¥Ü¡G¡u¦hµo©Êµw¤Æ¯g¦bµo¯fªì´Áªº2~3¦~¶¡¡A¬O¤ÏÂеo§@ªº°ª®p´Á¡A¦]¦¹¦b¯e¯fªì´Á¯à±µ¨ü¿n·¥ªvÀø¡A¯à¦³®Ä©µ½w¯e¯f¶iµ{¡A´î¤Ö¥¢¯àµ{«×(1)¡C­Õ­Y¯f±wªºÃĪ«¶¶±q«×¸û°ª¡A¹ï¹w«áª¬ªp¤]·|¦³«Ü¤jªºÀ°§U¡C°ê¥~´¿¸g§@¹L¤@¶µ¬ã¨s¡A¥ÎÃĶ¶±q©Ê¨Îªº±wªÌ¡Aµo¯f­·ÀI¥i´î¤Ö29%¡A³s±a­°§C37%ªº¦í°|­·ÀI¡A¥B¨ä¥LÂåÀø¶O¥Îªº¤ä¥X¤]·|´î¤Ö22%(2)¡C§Æ±æ³z¹L³o¨Ç²Î­p¼Æ¦r¡A¯àÅý¯f±wª¾¹D¡A¥u­n¯à°÷°t¦XÂåÅ@¤H­û·Ç½T¥ÎÃÄ¡Aµ´¹ï¹ï©ó¯f±¡±±¨î¦³À°§U¡C¡v

°ö¾i¨}¦nªºÂå¯fÃö«Y¡@¤Á²ö¥ô·N°±ÃļvÅT¯f±¡

³\¦h¯f±w¦b±oª¾¿©±w¦hµo©Êµw¤Æ¯g«á¡A¤ß²z¤W³q±`·|²£¥Í®£Äß¡AÄ~¦Ó¹ï¥Í¬¡²£¥Í°h«o¡C¦ý³\¦h¬ã¨sÅã¥Ü¡AÀHµÛ¥i¥H§ïµ½¯e¯f¶iµ{¬ÛÃöÃĪ«ªº¥X²{¡A¯f±w¥u­n¯à°÷¿n·¥ªº¡u«ö®É¡v¡B¡u·Ç½T¡v¥ÎÃÄ¡A¨ä¹êÁÙ¬O¯à°÷»P¦hµo©Êµw¤Æ¯g¦n¦n¦@¦s¡A¾Ö¦³¸û¨Îªº¥Í¬¡«~½è¡C¦¹¥~¥Ñ©ó¦hµo©Êµw¤Æ¯g¥i¯àÀH¯fµo¦ì¸m¦Ó¦³¤£¦Pªº¯gª¬¤ÏÀ³¡A¦]¦¹±wªÌ°£¤FªvÀø¥~¡A§óÀ³¸Ó¿n·¥»PÂåÅ@¤H­û«Ø¥ß¨}¦nªºÂå¯f·¾³q¡C

¿c¬Û¦pÂå®v´£¿ô¯f±w¡G¡u¦bÁ{§É¤Wµo²{¡A¦³¨Ç¯f±w¦]¬°¤@¬q®É¶¡¨S¦³µo§@¡A¦Û¥H¬°¯f¯g¤w¸g¦n¤F¦Ó¦Û¦æ°±ÃÄ¡A©Î¬O¦]¦P®É¦³¨ä¥L¯f¯gªºªvÀø¦Ó°±¤î¥ÎÃÄ¡Kµ¥±¡§Îµo¥Í¡C«Øij¯f±w³Ì¦n¯à¥ý¿Ô¸ßÂåÅ@¤H­ûªº·N¨£¡A¦]¬°§Y¨Ï¨S¦³Á{§É¯f¯gµo¥Í¡A¤¤¼Ï¯«¸g¤§µoª¢¤ÏÀ³«o¥i¯à«ùÄò¶i¦æ¤¤¡A¥u¬O¯f±w¨S¦³¹îı¡C¬°ÁקK¥ô¦ó´_µo¹ï©ó¨­Åé©Ò³y¦¨ªº¶Ë®`¡A«Øij¯f±w¦³¥ô¦ó°ÝÃD¡A³£­n¥ß§Y¤ÏÀ³µ¹ÂåÅ@¤H­û¡A¦P®É¤Á²ö¦Û¦æ°±ÃÄ¡A¤~¬O¥¿½Tªº°µªk¡C¡v

¦hµo©Êµw¤Æ¯g¬O¤@­Óªø´Á»P®É¶¡Áɶ]ªºªvÀø¹Lµ{¡AÁöµM¥Ø«e¨S¦³§¹¥þ®ÚªvªºÃĪ«¡A¦ý¥u­n¯à«ùÄò©Êªº¿í´`Âå®v«ü¥Ü¥ÎÃĪvÀø¡A´N¦³§U©ó­°§C´_µoªºÀW²v¡B©µªøµo§@®É¶¡¡C¦¹¥~¤Á²ö»´«H¤p¹D®ø®§©Î»´«H°¾¤è¡AÀ³±N©ÒÀò±o°T®§´£¥X¨Ó»PÂå®v°Q½×¡A¤~¬O¥¿½Tªº°µªk¡C

°Ñ¦Ò¸ê®Æ¡G

1. Goldberg LD, Edwards NC, Fincher C, Doan QV, Al-Sabbagh A, Meletiche DM. Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis.
J Manag Care Pharm. 2009 Sep;15(7):543-55.

2.Lizán L, Comellas M, Paz S, Poveda JL, Meletiche DM, Polanco C. Treatment adherence and other patient-reported outcomes as cost determinants in multiple sclerosis: a review of the literature. Patient Prefer Adherence. 2014 Dec 4;8:1653-64

¥»¤å¸g °·±dÂåÀøºô ±ÂÅv¥Zµn¡A­ì¤åµoªí©ó¦¹
¡i°·±dÂåÀøºô¡þ°OªÌ°ªº¸¨°³ø¾É¡j2016/05/10

ment,'script','//www.google-analytics.com/analytics.js','ga'); ga('create', 'UA-35937129-1', 'auto'); ga('send', 'pageview');